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use#LAARetinopathy of prematurity (ROP) is one of the leading 
causes of neonatal blindness in developed countries [1-4]. 
From the 16th week of gestation to birth, retinal blood vessels 
grow from the optic nerve to reach the peripheral retina [1]. 
However, premature birth and oxygen supplementation can 
arrest vascularization and form a defined border between 
the avascular and vascular retina [5]. Once the retina returns 
to ambient oxygen, vascular proliferation at this junction 
can induce the development of fibrovascular tissue (corre-
sponding to clinical stage 3 ROP) [5]. In advanced stage 
ROP, intense neovascularization encompasses the peripheral 
retinal surface forming fibrous tissues that contract and 
induce partial or total retinal detachment (stages 4 and 5, 
respectively) [1]. Accordingly, stage 5 ROP is character-
ized by a sequence of events including formation of a dense 
fibrovascular membrane that encompasses the entire inner 
retinal surface, contracts, producing funnel-shaped retinal 
detachment, and accumulation of proteinaceous fluid in the 
subretinal space [1]. Thus, blindness in ROP is the result of 
progressive, unrelenting neovascularization and ensuing 
retinal detachment and photoreceptor degeneration.
Neovascularization is regulated by a complex interplay 
between cytokines and immune cells, and usually includes 
a late stage inflammatory response. Angiogenesis is stimu-
lated by the release of factors such as vascular endothelial 
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Purpose: The clinical phenotype of advanced stage retinopathy of prematurity (ROP, stages 4 and 5) cannot be replicated 
in an animal model. To dissect the molecular events that can lead up to advanced ROP, we examined subretinal fluid 
(SRF) and surgically dissected retrolental membranes from patients with advanced ROP to evaluate its influences on 
cell proliferation, angiogenic properties, and macrophage polarity.
Methods: We compared our findings to SRF collected from patients with uncomplicated rhegmatogenous retinal detach-
ment (RD) without proliferative vitreoretinopathy and surgically dissected epiretinal membrane from eyes with macular 
pucker. All subretinal fluid samples were equalized for protein. The angiogenic potential of SRF from ROP eyes was 
measured using a combination of capillary cord formation in a fibrin clot assay, and its proliferative effect was tested 
with a DNA synthesis of human retinal microvascular endothelial cells. Findings were compared with SRF collected 
from participants with uncomplicated rhegmatogenous RD without proliferative vitreoretinopathy. The ability of SRF 
to induce nitric oxide production was measured in vitro using murine J774A.1 macrophages. Cytokine profiles of SRF 
from ROP and RD eyes were measured using a multienzyme-linked immunosorbent assay (ELISA). Fluorescent im-
munohistochemistry of retrolental membranes from ROP was performed to detect the presence of leukocytes and the 
composition of tissue macrophages using markers for M1 and M2 differentiation.
Results: The cytokine composition in SRF revealed that in ROP, not only were several proangiogenic factors were pref-
erentially elevated but also the profile of proinflammatory factors was also increased compared to the RD eyes. SRF from 
ROP eyes supported cell proliferation and endothelial cord formation while SRF from RD eyes had inhibitory effects. 
SRF from eyes with ROP but not RD robustly induced nitric oxide production in macrophages. Furthermore, fluorescent 
immunostaining revealed a preponderance of M1 over M2 macrophages in retrolental fibrous membranes from ROP 
eyes. The cytokine profile and biologic properties of SRF in ROP promote a proangiogenic environment, which supports 
the maintenance and proliferation of fibrous membranes associated with advanced stages of ROP. In contrast, SRF from 
RD eyes exhibits a suppressive environment for endothelial cell proliferation and angiogenesis.
Conclusions: Our investigation demonstrates that the microenvironment in advanced ROP eyes is proangiogenic and 
proinflammatory. These findings suggest that management of advanced ROP should not be limited to the surgical 
removal of the fibrovascular membranes and antiangiogenic therapy but also directed to anti-inflammatory therapy and 
to promote M2 activation over M1 activity.
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growth factor A (VEGF-A), platelet-derived growth factor 
(PDGF), and tumor necrosis factor α (TNF-α) among others 
[6]. VEGF-A, in particular, is elevated in early stages of ROP 
[7]. Ischemic sites also release chemotactic factors to recruit 
macrophages to the area, which further secrete VEGF-A 
to promote neovascularization [8,9]. Macrophages exhibit 
significant plasticity that allows them to change their pheno-
type depending on their environment. M1 macrophages are 
generally considered classically activated by interferon-γ 
(IFN-γ) or lipopolysaccharide (LPS) and exhibit proinflam-
matory properties. Alternatively activated M2 macrophages 
exhibit anti-inflammatory properties and are induced by 
interleukin-4 (IL-4) and IL-13 [10]. In the eye, macrophages 
are implicated in fibrovascular pathologies, including prolif-
erative diabetic retinopathy, choroidal neovascularization 
[11], and experimental oxygen-induced retinopathy, a model 
for early stage ROP [12]. It has been observed that inactivation 
of the monocyte lineage leads to suppression of pathologic 
angiogenesis in animals [13]. M1 polarized macrophages are 
associated with certain inflammatory ocular diseases such 
as age-related macular degeneration, while M2 macrophages 
have been described in a murine model of ischemic reti-
nopathy, in which they participate in tissue remodeling [14].
Although capillary obliteration and endothelial prolifera-
tion seen in early stages of ROP have been successfully repli-
cated in animal models of oxygen-inducted retinopathy [13], 
the advanced stage of the disease has yet to be induced in an 
animal model. In humans, advanced ROP is managed through 
dissecting fibrous membranes and releasing subretinal fluid 
(SRF) in an effort to reattach the detached retina. Unfortu-
nately, photoreceptor loss, retinal degeneration, and visual 
disability persist. Surgical specimens can be obtained from 
normally discarded tissue, including retrolental membranes 
(which cover the inner surface of the detached retina) and 
SRF filling the space between the detached retina and the 
RPE. These samples can be analyzed to understand the 
condition of the retinal microenvironment associated with 
advanced stages of ROP. In this study, we analyzed the cyto-
kine profile of SRF and the proangiogenic and proliferative 
potential of SRF, and compared our findings with those for 
SRF collected from retinal detachment without proliferative 
vitreoretinopathy.
METHODS
Specimen collection: Human SRF samples (n = 12) and retro-
lental membranes (n = 12) were obtained from 14 patients 
(ages, 4–8 months) who were undergoing open-sky vitrec-
tomy for stage 5 ROP. Retrolental membranes in stage 5 ROP 
were bluntly dissected from the underlying detached retina. 
SRF was tapped externally into a tuberculin syringe only 
when clinically indicated. Effort was made to ensure that SRF 
was not contaminated with blood. Patients with other known 
concurrent ocular conditions such as glaucoma, congenital 
anomalies, or inflammatory diseases were excluded. SRF 
samples were collected from patients who had developed 
acute retinal detachment (RD) of less than 48 h onset as the 
control samples. SRF samples were centrifuged at 16,128 
rcf at 4 °C for 20 min, and supernatants were aliquoted for 
further experiments.
Ethics statement: This study was approved by the Institution 
Review Boards (IRBs) of Massachusetts Eye and Ear and 
Schepens Eye Research Institute. The study protocol adhered 
to the Declaration of Helsinki for research involving human 
patients. The participants provided written consent and 
approved the consent procedure for our studies. The study 
was discussed in detail with the parents or legal guardians. 
After discussing any questions and concerns, a detailed IRB-
approved consent form was presented to them, and written 
permission was obtained. These specimens were collected 
from patients who signed the appropriate consent forms and 
had agreed to participate in the study.
Bio-Plex cytokine array: The Bio-Plex human cytokine 
22-Plex panel (Bio-Rad Laboratories, Hercules, CA) was 
used to measure cytokine composition and concentration in 
the SRF of patients with ROP and RD. Antibodies used in 
this cytokine array included Eotaxin, granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage (GM)-
CSF, IFN-γ, IL-1ra, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, 
IL-12p70, IL-13, IL-15, interferon gamma-induced protein 
10 (IP-10), macrophage inflammatory protein 1α (MIP-1α), 
MIP-1β, regulated and normal T cell expressed and secreted 
(CCL5) (RANTES), PDGF-BB, TNF-α, and VEGF-A. The 
procedure has been reported in previous studies [15,16]. 
Briefly, a 96-well filter plate was wetted with 100 μl assay 
buffer solution and vacuum filtered. Anticytokine bead solu-
tion (50 μl) was added to each well, followed by vacuum 
filtration and two successive buffer washes. SRF samples 
were diluted sixfold with human serum diluent (Bio-Rad 
Laboratories), and 50 μl diluted samples was added to each 
well. Wells were shaken at 37 shakes per s, 0.5 shakes pert s, 
vacuum filtered, and washed with buffer three times. Detec-
tion antibody (25 μl) was added per well, and the shaking and 
washing procedure was repeated. Streptavidin-PE (50 μl) was 
then added to each well, shaken at 0.5 shakes per s, vacuum 
filtered, and washed with buffer. After a final shaking at 37 
shakes per s, the plate was docked for reading by the auto-
mated assay machine (Bio-Plex 200 System, Bio-Rad).Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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Cell proliferation assay: DNA proliferation assay was 
performed using human retinal microvascular endothelial 
cells (HRMECs) kindly provided by Dr. Patricia D’Amore 
(Schepens Eye Research Institute/Mass Eye and Ear, Boston, 
MA). Cells were plated at a sub-confluent density of 1 × 103 
cells/well in a 96-well plate in EBM-2 medium (endothelial 
cell growth media kits, Lonza) supplemented with growth 
factors for 24 h (37 °C, 5% CO2). The medium was then 
replaced with basal EBM-2 medium without growth factors, 
and incubation was continued for 1 day (37 °C, 5% CO2). 
Cells were then stimulated with basal EBM-2 medium, 10% 
SRF from RD eyes (diluted in basic EBM-2 medium), 10% 
SRF from ROP eyes (diluted in basic EBM-2 medium), or 
VEGF-A (10 ng/ml, 50 ng/ml, and 100 ng/ml), respectively. 
After 12 h, a colorimetric proliferation assay (CyQUANT 
NF Cell Proliferation Assay Kit, Invitrogen, Grand Island, 
NY) was used to estimate the cell proliferation according to 
the user instruction. A fluorescence microplate reader with 
excitation at 485 nm and emission detection at 530 nm was 
used to measure the fluorescence intensity of each sample. 
The negative control (basal medium) of cell proliferation was 
normalized to 100% using the actual value of cell prolifera-
tion dividing itself. Similarly, the actual values of cell prolif-
eration yielded in other conditions were used to divide the 
control for the normalization.
Dead/live cell assay: Dead/live cell assay was performed 
to determine whether SRF from patients with RD induced 
endothelial cell toxicity. HRMECs were plated in 96-well 
plates (2,000 cells/well). After adhesion, wells were washed 
in 1× PBS (10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl; 
137 mM NaCl, pH 7.4) and incubated for 24 h in the following 
media: basal EBM-2 medium, full medium (basal medium 
with all necessary supplements and growth factors, Lonza), 
10% of SRF from patients with RD diluted in basal medium, 
and 1, 10, and 50 µg/ml mitomycin-C (positive controls). 
Culture medium was slowly removed from each well. Cells 
were gently washed in 1× PBS one time. Cells were stained 
with Calcein AM/EthD-1 (Live/Dead cytotoxicity kit, Invit-
rogen) according to the manufacturer’s instructions. Calcein 
AM (0.5 µl) and EthD-1 (1.5 µl) were diluted in 1× PBS 
(2.5 ml; 30–50 µl per well). Cells were imaged and counted 
for green (live) and red (dead) fluorescence. Cell morphology 
was also examined under an inverted microscope (Olympus, 
Model IX51, Avon, MA). Data are presented as the average of 
the dead cell rate [dead cells/(dead cells + live cells) × 100%].
Angiogenesis assay: Three-dimensional fibrin clot was 
used for the in vitro angiogenesis assay modified from a 
previous procedure [17]. Fibrinogen (Sigma, St. Louis, MO) 
was dissolved in 1× PBS to a concentration of 10 mg/ml and 
dialyzed overnight in 1× PBS (pH 7.4) using a drop dialysis 
method over dialysis paper (Filter 47 mm, 0.025 µm, Milli-
pore, Billerica, MA). This resulted in a protein concentration 
of 4.3–4.7 mg/ml. Fibrinogen was then sterile-filtered to a 
final concentration of 1.0–1.5 mg/ml in 1× PBS and added to 
each well of a 24-well plate. Thrombin (0.635 U/ml; Sigma) 
was then added, mixed, and pipetted (250 µl) into each well. 
Fibrin clots were formed at room temperature. Human micro-
dermal capillary endothelial cells (HMCECs, Invitrogen/
Cascade Biologics, Portland, OR) 5 × 104 cells per well were 
added to the surface of the fibrin clots and incubated for 1 h 
(37 °C, 5% CO2). The medium was removed, and a top layer 
of 250 μl fibrinogen/thrombin mixture was pipetted over the 
cells. SRF from the ROP and RD samples was protein equal-
ized to various concentrations (0.1%, 1.0%, 5.0%, and 10.0%) 
in Dulbecco’s Modified Eagle Medium (DMEM; BioWhit-
taker, Walkersville, MD) and was placed in wells in a masked 
fashion. DMEM supplemented with VEGF-A (10 ng/ml) 
and 0.1% FBS were used as positive and negative controls, 
respectively. Each assay was performed in triplicate. After 72 
h, wells were fixed with 4% paraformaldehyde. Five repre-
sentative fields per well were photographed with an Olympus 
inverted microscope. Total mean cord lengths (µm/well) were 
measured using the NIH Image program (ImageJ 1.46).
Nitrite assay for macrophage activation: Murine J774A.1 
macrophages, which have been previously studied [18], were 
plated at a concentration of 1.5 × 105 cells per well in a 96-well 
culture plate (37 °C, 5% CO2) and cultured for 2 h in DMEM 
with supplements (0.1 M HEPES, 0.1% BSA, 1% nones-
sential amino acid, 1 µg/ml iron-free transferrin, 10 ng/ml 
linoleic acid, 0.3 ng/ml Na2Se and 0.2 µg/ml Fe(NO3)3, 2 mM 
L-glutamine, and 2 mM sodium pyruvate and gentamycin). 
The supernatants were removed, and the macrophage mono-
layer was washed twice with fresh medium. Macrophages 
were incubated (37 °C, 5% CO2) with E. coli LPS (Sigma) 
at a concentration of 1 µg/ml (positive control), medium 
(negative control), or with 10% of SRF from the ROP and 
RD samples (diluted in the same medium). After 24 h, the 
supernatant (75 µl) from individual wells was mixed with 
deionized water (65 µl), and the mixture solution (10 µl) of 
N-1-naphthylethylenediamine-HCl (0.1%) and sulfanilamide 
(1.0%; volume ratio 1:1) in acetic acid (60%, Griess reagent, 
Molecular Probes, San Jose, CA). The plate was then incu-
bated for 10 min in the dark as described previously [19]. 
Nitrite concentration in 100 μl of cell culture supernatant 
using the Griess reagent was then determined for each well by 
measuring the optical density at 550 nm [20]. All experiments 
were done in triplicate.Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
884
Tissue preparation and immunohistochemistry: After 
surgical removal, fibrous membranes were collected from 12 
patients with stage 5 ROP and prepared for frozen sections. 
Sections were incubated with primary antibodies, followed 
by successive 1× PBS washes (30 min in total) and incuba-
tion with fluorescent secondary antibodies Cy2 and Cy3 
in the dark for 40 min. Slides were photographed with an 
Olympus digital inverted microscope. For comparison, 
ERMs obtained from five patients with macular pucker were 
subjected to staining and cell count. Fluorescent micrographs 
of five representative regions from each section were used 
for cell counting. Cells expressing the marker of interest 
and total cells per-field were tabulated for each section and 
calculated as a ratio of positive over total cell number. Posi-
tive cells were defined as those exhibiting positive staining 
for the fluorescent marker in their cytoplasm and possessing 
nuclei identified with 4’,6-diamidino-2-phenylindole (DAPI) 
staining. The following antibodies were used in immuno-
histochemistry: CD40 and CD260 (LifeSpan BioSciences, 
Seattle, WA), inducible nitric oxide synthase (iNOS; R&D 
System, Minneapolis, MN), and arginase I (LifeSpan BioSci-
ences). Secondary antibodies, Cy2 and Cy3, were purchased 
from Abcam (Cambridge, MA).
Data analysis: The Student t test was used to compare differ-
ences in the capillary cord formation of HMCECs cultured 
in RD and ROP SRF. Other statistical analysis in this study 
was subjected to the Wilcoxon signed-rank test according to 
the non-normal distribution. To establish linear regressions, 
natural logarithm transformation (Ln-transformation) was 
performed to normalize data collected from the dose-depen-
dent formation of capillary cord induced by SRF from ROP 
and RD eyes [21]. The data are presented as mean ± standard 
error of the mean (SEM). All specific analyses and regres-
sions were performed in Sigma Plot 11.0 (San Jose, CA). The 
level of significance p value was set at <0.05.
RESULTS
Angiogenic and inflammatory cytokines in subretinal fluid: 
Differences in the cytokine expression profiles of SRF 
from ROP and RD eyes were measured using a multiplex 
(Bio-Plex) immunoassay. Of the 22 inflammatory cytokines 
evaluated (Table 1), three had significantly higher levels in 
the RD samples compared to the ROP samples (G-CSF, IL-6, 
and IFN-γ, all p<0.05). From the same set of cytokines, there 
were significantly higher amounts of the proangiogenic and 
proliferative cytokines, VEGF-A and PDGF-BB, and the 
chemotactic cytokines, MIP-1α, MIP-1β, and RANTES (all 
p<0.05) in the SRF from the ROP eyes than in the SRF from 
the RD eyes. In addition, there was significantly more IL-1ra 
in the SFR from the ROP eyes (both p<0.05). There were no 
significant differences in the cytokine concentrations in the 
SRF for eotaxin, GM-CSF, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, 
IL-12p70, IL-13, IL-15, IP-10, and TNF-α (Table 1). These 
results show that there are differences in the cytokine profiles 
of SRF from RD and ROP eyes. These differences are related 
to the expression of more potentially proangiogenic, chemo-
tactic, and proliferative cytokines in the SRF of ROP eyes.
Proliferative effects of subretinal fluid: To further study the 
biologic effects of proliferative cytokines present in the SRF 
of ROP eyes, the ability of SRF to induce proliferation in 
HRMECs was measured. The SRF from ROP eyes signifi-
cantly promoted proliferation; in contrast, SRF from RD 
eyes significantly suppressed proliferation. Compared to the 
medium as the negative control, SRF from ROP eyes induced 
about an 80% increase in DNA proliferation of HRMECs, 
respectively. Conversely, SRF from RD eyes inhibited 
HRMEC proliferation by 50% (Figure 1A). In addition, 
different concentrations of VEGF-A stimulated HRMECs 
at least as much as SRF from ROP eyes (156%, 209%, and 
145%, respectively; Figure 1A). Statistical significance was 
measured between every two culture conditions for cell 
proliferation, and all p values are listed in Figure 1B. Our 
data show that SRF from ROP eyes promoted endothelial 
cell proliferation, while SRF from RD eyes inhibited this 
response.
Using the dead/live cell assay, we observed that the mean 
dead cell rate for HRMECs grown in 10% of RD SRF was 
low (11.9±0.9%) and similar to that for HRMECs grown in 
full medium (9.2±4.0%; p>0.05). The dead cell rate in basal 
medium was 19.0±3.7%. In addition, there were no observ-
able differences between the morphology of HRMECs grown 
in 10% of RD SRF versus those grown in full medium 
(Figure 1C). In contrast, the mean dead cell rate for cultured 
HRMECs in various concentrations of mitomycin-C was 
much higher (21.8±3.1% at 1 µg/ml, 29.9±6.1% at 10 µg/ml, 
and 34.0±2.0% at 50 µg/ml) than that in RD SRF (all p<0.05, 
Figure 1C). These data confirm that SRF from RD eyes 
inhibit endothelial cell proliferation without inducing detect-
able toxic effects on cell survival and morphology in vitro.
Effects of subretinal fluid on capillary cord formation: To 
evaluate the angiogenic properties of SRF, a three-dimen-
sional fibrin clot model was used. Capillary cord was formed 
in all culture conditions, and the cord length from medium 
alone was longer than that from cultured in the mixture 
medium with SRF from patients with RD (Figure 2A). SRF 
from ROP eyes at concentrations of 5.0% (11,779±33 µm) 
and 10.0% (10,570±33 µm) significantly enhanced cord 
length formation compared to the negative control (0.1% Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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of FBS, 5,910±22 µm; both p<0.05). However, the 0.1% 
(3,780±30 µm) and 1.0% (7,428±18 µm) concentrations did 
not show any significant enhancement (both p>0.05; Figure 
2A). Compared to the positive control (VEGF-A, 10 ng/ml), 
SRF from ROP eyes at the concentration of 1.0%, 5.0%, 
and 10.0% had similar enhancement effects on capillary 
cord formation (Figure 2A). Conversely, SRF from RD eyes 
inhibited capillary cord formation. At concentrations of 1.0%, 
5.0%, and 10.0%, there was a significant decrease in capillary 
formation compared to the (0.1% of FBS) negative control 
(all p<0.05, Figure 2A). At lower concentrations, the effects 
of SRF from RD eyes on cord length were not significantly 
different from those of the negative control (p>0.05, Figure 
2A). Therefore, SRF from ROP eyes induced capillary tube 
formation in a positive dose-dependent manner. Specifically, 
the capillary cord formation was positively associated with 
the concentration of SRF from ROP eyes, but negatively asso-
ciated with the concentration of SRF of RD eyes (Figure 2B). 
These in vitro assays demonstrate that SRF from ROP eyes 
exhibits proangiogenic properties, while SRF from RD eyes 
are possibly angiostatic. A detailed comparison (p values) of 
SRF on capillary cord formation between every two different 
culture conditions is listed in Table 2.
Production of nitric oxide from macrophages induced by 
subretinal fluid: To determine whether SRF from ROP eyes 
activates macrophages and potentially promotes inflamma-
tion, the ability of SRF to induce nitric oxide production in 
macrophages was assessed. The nitrite levels in the condi-
tion media relative to the nitric oxide levels generated by 
the macrophages was significantly higher in the cultures of 
macrophages treated with SFR from ROP eyes and at the 
same level of macrophages stimulated with LPS (Figure 3A). 
In contrast, SRF from RD eyes stimulated no more nitrate 
than the macrophages at rest (Figure 3A). Statistical signifi-
cance was measured between every two culture conditions on 
nitric oxide production, and all p values are listed in Figure 
3B. This demonstrates that along with the proangiogenic 
activity there is proinflammatory support by the SRF of ROP 
eyes as suggested by their cytokine profile.
Macrophages in retrolental membranes express M1 polarity: 
Results demonstrate that the SRF from ROP eyes potentially 
promotes angiogenesis and inflammation. This suggests 
Table 1. The concenTraTion (pg/ml) of cyTokines in srf from rop and rd eyes using bio-plex cyTokine array.
Cytokines ROP (n=10, min – max) RD (n=10, min – max) P
Eotaxin 6.5±0.2 (6.36 – 6.72) 10.7±7.0 (2.70 – 21.78) ≥0.05
G-CSF 76.4±41.7 (34.80 – 117.90) 2421.8±801.9 (366.48 – 2421.78) <0.001
GM-CSF 26.5±8.1 (18.36 – 34.68) 24.9±4.3 (19.56 – 31.50) ≥0.05
IFN-γ 12.3±1.2 (11.10 – 13.44) 34.0±16.8 (14.88 – 60.54) <0.05
IL1-ra 11,330.2±5570.0 (5758.38 – 16,902.00) 88.8±32.5 (37.92 – 126.42) <0.001
IL-4 0.2±0.2 (0.00 – 0.36) 0.7±0.4 (0.18 – 1.38) ≥0.05
IL-5 142.1±132.7 (9.42 – 274.80) 10.1±12.4 (0.00 – 30.30) ≥0.05
IL-6 209.2±52.3 (156.78 – 261.60) 5274.8±2005.4 (2082.00 – 7503.48) <0.001
IL-7 3.8±1.3 (2.52 – 5.10) 11.6±2.3 (9.48 – 15.48) ≥0.05
IL-8 845.8±776.4 (69.48 – 1622.04) 115.1±21.9 (95.94 – 150.30) ≥0.05
IL-9 24.1±8.4 (15.72 – 32.52) 18.8±5.5 (15.18 – 27.78) ≥0.05
IL-10 11.9±7.8 (4.08 – 19.74) 3.7±1.9 (0.66 – 5.70) ≥0.05
IL-12p70 3.4±1.3 (2.10 – 4.62) 1.8±0.7 (0.66 – 2.58) ≥0.05
IL-13 2.4±0.7 (1.68 – 3.12) 0.9±0.6 (0.06 – 1.62) ≥0.05
IL-15 6.1±5.5 (0.60 – 11.64) 19.6±8.0 (12.90 – 32.64) ≥0.05
IP-10 16,431.9±4567.9 (11,860.74 – 21,000.00) 15,788.5±3248.4 (10,564.86 – 19,198.02) ≥0.05
MIP-1α 13.6±9.3 (4.38 – 22.86) 1.5±0.9 (0.00 – 2.28) <0.05
MIP-1β 376.1±266.6 (109.44 – 642.78) 63.4±21.3 (33.36 – 93.48) <0.001
RANTES 950.7±21.2 (929.46 – 971.94) 0.5±0.6 (0.00 – 1.38) <0.05
PDGF-BB 47.0±9.4 (37.62 – 56.46) 12.1±10.9 (0.00 – 29.40) <0.05
TNF-α 16.0±0.2 (15.72 – 16.20) 18.7±3.4 (14.52 – 23.88) >0.05
VEGF-A 11,522.6±3160.1 (8362.20 – 14,682.90) 601.4±389.6 (117.30 – 1200.60) <0.001Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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Figure 1. Effects of subretinal 
fluid from eyes with retinopathy 
of prematurity and retinal detach-
ment on the proliferation of human 
retinal microvascular endothelial 
cells; evaluation of toxic effect 
of subretinal fluid from patients 
with retinal detachment on human 
retinal microvascular endothelial 
cells. A: Data were normalized 
to the mean values of the human 
retinal microvascular endothelial 
cells (HRMECs) grown in medium 
alone. Subconfluent cultures were 
incubated with 10% concentrations 
of subretinal fluid (SRF) from eyes 
with retinopathy of prematurity 
(ROP) and retinal detachment 
(RD). SRF from ROP eyes induced 
an increase in the proliferation 
effect while SRF from RD eyes 
showed a modest inhibitory effect. 
Vascular endothelial growth factor 
A (VEGF-A; 10–100 ng/ml) was 
used as the positive control. B: 
The dead cell rates (the dead cell 
rate=the number of dead cells/the 
number of (dead cells + live cells) 
x 100%) of HRMECs cultured in 
different conditions.Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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that monocytes that migrate to the fibrovascular membranes 
would be polarized to into either M1 macrophages to mediate 
inflammation or to M2 macrophages that would contribute to 
the proangiogenic state of the SRF. Immunostaining of these 
membranes for CD40 and CD206 (representing M1 and M2 
polarity, respectively) showed a preponderance of CD40 over 
CD206 markers (Figure 4A). Expression of the M1 intracel-
lular enzyme iNOS and the M2 intracellular enzyme arginase 
1 was sporadic (Figure 4B–C). Overall, the expression of M1 
over M2 markers in retrolental membranes from ROP eyes 
increased eightfold (88.8±7.0% versus 11.2±7.0%, p<0.001, 
Figure 4D). This demonstrates that these proangiogenic and 
Figure 2. Three-dimensional fibrin 
clot model of cord formation by 
human microdermal capillary 
endothelial cells incubated with 
subretinal fluid from eyes with reti-
nopathy of prematurity and retinal 
detachment. The capillary cord was 
formed in all culture conditions and 
indicates that the cord length from 
the medium alone was longer than 
that from cells cultured in a medium 
containing SRF from patients with 
retinal detachment (RD). A: Subret-
inal fluid (SRF) from eyes with 
retinopathy of prematurity (ROP) 
induced cord formation in human 
microdermal capillary endothelial 
cells (HMCECs) while SRF from 
eyes with RD showed shorter length 
measurements (Student t test, n = 
10/group, * p < 0.05, Mean±SEM, 
please see Table 2 for detailed 
comparisons). Vascular endothelial 
growth factor A (VEGF-A; 10 ng/
ml) and 0.1% fetal bovine serum 
(FBS) were used as positive and 
negative controls, respectively. 
B: A linear association was found 
between the cord length and the 
SRF concentration (ROP, positive; 
RD, negative). The cord length and 
the SRF concentration were natural 
logarithm (Ln)-transformed to 
establish the linear models.Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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proinflammatory cytokines mediate development of M1 and 
M2 macrophage polarity in the fibrous membranes of eyes 
with ROP.
DISCUSSION
We evaluated the cytokine levels in the SRF from young 
patients with ROP and RD. The measurements indicated 
that the concentration varied among individuals. ROP is 
not a common eye disease, and collecting enough SRF 
from patients with ROP to make a meaningful analysis is 
difficult. Recent studies showed that among 383 preterm 
infants screened for ROP, only one had stage 5 disease [22]. 
Additionally, in most cases, SRF is not routinely drained (and 
collected) during surgical collection of advanced stage ROP. 
Therefore, collecting a large sample of SRF is difficult since 
advanced ROP is an orphan disease and surgical drainage of 
SRF is not routinely performed. A previous study indicates 
that the protein concentration of SRF varies with the dura-
tion of RD [23]. Thus, it may be easy to observe individual 
variations in the cytokine concentration in these patients. 
This leads to the large standard divisions. In addition, the 
cytokine concentration in SRF covered a wide range in a 
recent study even though the cytokine levels were calculated 
from an appropriately large sample population [24].
ROP is a condition in which the hyperoxic environment 
inhibits programmed (and possibly VEGF-driven) retinal 
vasculogenesis [25], and the early stage has been recapitu-
lated in the oxygen-induced model of retinopathy [13]. In this 
model, the normal vascularization pattern is interrupted, as 
blood vessels fail in their progress to reach the ora serrata 
of the retina [26]. When animals are returned to ambient 
oxygen, the avascular retina releases VEGF-A and other 
factors to induce vessel growth [25]. This robust fibrovas-
cular response promotes endothelial cell proliferation and 
migration beyond the inner limiting membrane of the retina 
and toward the vitreous cavity, forming atypical fibrous 
tissues, which can exert traction on the retina and cause its 
detachment [1]. We supposed that SRF from patients with 
ROP would enhance cell proliferation and vessel formation 
because one of the typical clinical characteristics of ROP is 
the development of fibrovascular tissue that can lead to partial 
or total retinal detachment [1]. This also indicates that SRF 
from patients with ROP enhances human cellular and fibrous 
proliferation. The Bio-Plex cytokine array analysis indicates 
that the concentration of VEGF-A in SRF was relatively 
high (11,522.6 pg/ml). Previous studies proved that VEGF-A 
could significantly provoke fibrous proliferation [27-30] in 
a broad aspect from human to low-level vertebrates. We 
therefore performed our proliferation assays on HRMECs, 
representing microvascular and macrovascular cells. In the 
current study, medium of SRF from patients with ROP had 
significant effects on proliferation even though the cytokine 
concentration was relatively low in the culture condition. 
Table 2. pairwise mulTiple comparison of srf on capillary cord forma-
Tion beTween every Two culTure condiTions (p values).
Culture media 0.1% of FBS 10 ng/ml of VEGF 0.1% of ROP 1.0% of ROP 5.0% of ROP
10 ng/ml of VEGF 0.000
0.1% of ROP 0.093 0.083
1.0% of ROP 0.338 0.565 0.034
5.0% of ROP 0.520 0.903 0.254 0.795
10.0% of ROP 0.048 0.576 0.010 0.150 0.599
Culture media 0.1% of FBS
10 ng/ml of 
VEGF
0.1% of RD 1.0% of RD 5.0% of RD
10 ng/ml of VEGF 0.000
0.1% of RD 0.306 0.441
1.0% of RD 0.140 0.082 0.042
5.0% of RD 0.104 0.084 0.007 0.613
10.0% of RD 0.021 0.044 0.001 0.716 0.087
Culture media 0.1% of ROP 1.0% of ROP 5.0% of ROP 10.0% of ROP
0.1% of RD 0.004 0.757 0.711 0.073
1.0% of RD 0.600 0.060 0.217 0.017
5.0% of RD 0.990 0.037 0.254 0.010
10.0% of RD 0.055 0.011 0.162 0.005Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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Based on this observation, we postulate that the cytokine 
concentration in SRF from patients with ROP could be high 
enough to enhance the proliferation and angiogenesis in vivo.
In the early clinical stages of ROP, the fibrovascular 
tissue generally regresses, and normal retinal vasculariza-
tion resumes. However, little is known about advanced stage 
ROP and why eyes with early stage ROP progress to more 
advanced stages, as this phenomenon cannot be replicated in 
an animal model. In this study, we extracted SRF and fibro-
vascular membranes from patients with advanced ROP and 
analyzed their cytokine profile and distribution of immune 
cells involved to better define the molecular and cellular 
participants of advanced ROP. In vitro assays for capillary 
formation and endothelial proliferation showed that SRF 
from ROP eyes induced robust support for these cellular 
processes similar to VEGF-A. Interestingly, SRF from RD 
eyes showed inhibitory effects on both processes. This inhibi-
tory effect diminished with dilution suggesting the presence 
of an inhibitor. In the present study, HMCECs were used to 
study cord structure formation instead of using HRMECs, 
which have been used to study the formation of capillary or 
capillary-like structures in vitro [31-33]. For an additional 
comparison to HRMECs, we used HMCECs to evaluate the 
ability of VEGF-A on the formation of capillary-like struc-
tures. Continuous neurovascular development in the retina is 
a typical feature of ROP, and VEGF-A plays an important role 
in stimulating vasculogenesis and angiogenesis. When we 
assayed SRF from ROP eyes, we observed that proangiogenic 
cytokines VEGF-A and PDGF-BB were elevated compared to 
SRF from RD eyes. In comparison, G-CSF, IFN-γ, and IL-6 
associated with acute inflammation, antigen presentation, and 
subsequent cell-mediated responses had lower concentrations 
Figure 3. Nitrite production in 
cultured macrophages incubated 
with subretinal fluid from eyes 
with retinopathy of prematurity and 
retinal detachment. A: Subretinal 
fluid (SRF) from eyes with retinop-
athy of prematurity (ROP) induced 
robust production of nitrite at 
levels similar to lipopolysaccharide 
(LPS; positive control; Wilcoxon 
signed-rank test, - p ≥ 0.05, *p < 
0.05, **p < 0.001). SRF from eyes 
with retinal detachment (RD) did 
not have any measurable effects. 
B: Detailed comparison of nitrite 
production between every two 
different conditions, for instance, 
p > 0.05 between macrophage and 
medium, p < macrophage + LPS 1 
μg/ml versus medium.Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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Figure 4. Immunohistochemical 
localization for macrophages in 
retrolental membranes from eyes 
with retinopathy of prematurity. 
A: Expression of CD40 (repre-
senting M1 polarity; arrows) and 
CD206 markers (representing M2 
polarity; arrowheads) in tissue 
macrophages associated with 
retinopathy of prematurity (ROP) 
tissue. B–C: Antihuman inducible 
nitric oxide synthase (iNOS) and 
arginase antibodies were also used 
to detect M1 and M2 macrophages, 
respectively. D: Distribution of M1 
and M2 macrophages in retrolental 
membranes from eyes with reti-
nopathy of prematurity (ROP); the 
predominant macrophage is the M1 
type, and there is only a limited 
number of M2 type macrophages 
(** p<0.001). Scale bar = 20 µm.Molecular Vision 2014; 20:881-893 <http://www.molvis.org/molvis/v20/881> © 2014 Molecular Vision 
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in the ROP specimens than in the RD specimens. These find-
ings correlate with the pathophysiology of RD as an acute 
inflammatory or wound healing process [34].
Our results show that in the membranes of ROP eyes 
there is a mix of M1 and M2 macrophages with M1 macro-
phages outnumbering M2 macrophages. Therefore, these 
membranes harbor proangiogenic M2 macrophages. The 
lack of significant levels of proinflammatory cytokines 
suggests that the M1 macrophages are either inactive or are 
a source of the chemokines that promote cellular infiltration. 
It is also possible that they arose from an earlier inflamma-
tory response. This would suggest the neovascularization 
in advanced ROP might well be a result of an inflamma-
tory response that transitions to an unregulated M2 wound 
repair response. The results clearly demonstrate that retinal 
microenvironment of advanced ROP is proangiogenic and 
proinflammatory.
Numerous cytokine studies are available, but there is 
not much comparable data on cytokine concentration of SRF 
from young patients with ROP. Compared to the cytokine 
concentration in SRF of patients with RD in a previous study 
[24], the levels of proinflammatory cytokines were much 
higher in our study, including IL-6 (209.2 pg/ml versus 60 pg/
ml), INF-γ (12.3 pg/ml versus <0.3 pg/ml), TNF-α (16.0 pg/
ml versus 6.2 pg/ml), and IL-15 (6.1 pg/ml versus 0.8 pg/ml). 
M1 macrophages secrete many cytokines, such as IL-6 and 
TNF-α. The concentrations of proinflammatory cytokines, 
which are closely related to M1 macrophages, are relatively 
high in our study. This might be largely due to the eightfold 
higher number of M1 macrophages compared to M2 macro-
phages detected in the retrolental membranes of patients with 
ROP. In our study, the medium with SRF of patients with 
ROP had significant effects on proliferation and angiogenesis 
even though the actual cytokine concentration was relatively 
low in the culture condition. Therefore, we supposed that the 
SRF of patients with ROP must be high enough to enhance 
proliferation and angiogenesis in vivo.
In the culture situation, we did not find obviously toxic 
effects on the antiproliferation of HRMECs. HRMECs grew 
quite well in the medium with SRF from the patients with RD 
although the proliferation was significantly slower compared 
to other culture situations. However, an exaggerated inflam-
matory response was observed in some patients with RD [24], 
and an accumulation of lactic acid and dextrose was found in 
patients with long-duration RD [23]. Phospholipids are also 
increased in SRF, which reflects increased apoptosis leading 
to retinal degeneration [23]. (Phosphatidylserine externaliza-
tion expressed on the outer membrane of apoptotic cells is 
the “eat me” signal for phagocytes [35]). HRMECs were also 
used to estimate the toxic effect of SRF from patients with 
RD. But no such toxic effects were observed on the survival 
and morphology of HRMECs in vitro.
Our findings implicate macrophages in fibrovascular 
membranes and their specific products such as proangio-
genic cytokines (found in the SRF) to transition from early 
to advanced stage ROP. Suppression of angiogenic and 
proliferative cytokines, in particular VEGF-A and PDGF-BB, 
may prevent disease progression from earlier stages. This is 
supported by recent evidence that anti-VEGF-A agents such 
as bevacizumab (Avastin) can control and slow progression 
of ROP [36]. However, in parallel to anti-VEGF-A therapy, 
strong consideration should be given to anti-inflammatory 
therapy to control the deleterious actions of M1 macrophages 
and possibly recruitment of microglia. For example, down-
regulation of MIP-1α and MIP-1β can reduce macrophage 
recruitment and diminish their role in neovascularization 
and inflammation. Possible combinatorial therapy including 
antiangiogenic and anti-inflammatory agents could have a 
strong positive clinical effect in controlling the progression 
of advanced ROP.
The cytokine profile and biologic properties of SRF 
from ROP eyes promote a proangiogenic environment that 
supports the maintenance and proliferation of fibrovas-
cular membranes associated with advanced stages of ROP. 
In contrast, the properties of SRF from RD eyes exhibit a 
suppressive environment for endothelial cell proliferation 
and angiogenesis. Induction of iNOS by SRF from ROP eyes 
in vitro and the observed preponderance of CD40 positive 
over CD206 positive macrophages in fibrovascular tissues 
suggest predominance of M1 over M2 polarity and support a 
potentially strong concurrent proinflammatory environment. 
These findings suggest that management of advanced ROP 
should not be limited to antiangiogenic therapy but also target 
the inflammatory component.
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